Quantitative immunohistochemical expression of GP88 in invasive ductal carcinoma (IDC) of human breast cancer
Introduction: Progranulin or acrogranin is an 88-kDa glycoprotein identified by a biological screen for protein targets associated with high tumorigenicity. This work was aimed to investigate the digital expression of GP88, and HER2/neu as a predictive biomarker in human invasive ductal carcinoma (I...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Emergency Department of Hospital San Pedro (Logroño, Spain)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/5c4f9560f10441b3b12802d30dac59d2 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Introduction: Progranulin or acrogranin is an 88-kDa glycoprotein identified by a biological screen for protein targets associated with high tumorigenicity. This work was aimed to investigate the digital expression of GP88, and HER2/neu as a predictive biomarker in human invasive ductal carcinoma (IDC) versus benign tumors and normal breast tissues, as well as its correlation with different pathological parameters.
Methods: The immunohistochemical avidin-biotin complex protocol of the paraffin section was used to detect the expression of GP88 and HER2/neu in IDC of 60 patients, 30 benign, and ten normal breast tissues.
Results: The study showed a high expression of GP88 in IDC comparing to normal and benign breast tissues. A higher significant statistical correlation between the expression of GP88 and large tumor size, tumor grade, and lymph node metastasis (LNM). While a negative statistical correlation was noticed between the expression of GP88 and ER, PR, and HER2/neu status.
Discussion: The results of the quantitative immunostaining density of GP88 glycoprotein antibody revealed it to be a valuable predictive and therapeutic marker of GP88 in human IDC patients. |
|---|